Back to Awarded Treatment Trials
Awarded Trial: 22T-001
Grant ID
22T-001
Illness
Schizophrenia
Primary Drug/Intervention
Intravenous immunoglobulin
Primary Dosage
2g/kg over two 2-6 hr periods
Secondary Drug Intervention
Rituximab
Secondary Dosage
2 infusions of 1 g over 2-4 hr
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Enrolling
Investigator
Belinda Lennox
Sample Size
56
Duration of Study Period for Each Subject
50 days
Outcome Measurements
Primary outcome is the time to start of symptomatic recovery, which is defined as symptomatic remission sustained for at least 6 months. Symptomatic remission is defined as a score of 3 or less on each of the following PANSS items: P1, P2, P3, N1, N4, N6, G5, G9. Secondary outcomes include: time to symptomatic remission, relapse, number of adverse events of the 12-month follow-up period, number of serious infections, proportion of patients reaching 20%, 30% and 40% reduction in PANSS total score of the 12-month follow-up period.
Results
N/A
Publication
N/A
Link
N/A
PI Name
Belinda Lennox
Degree
N/A
Center
Department of Clinical Neurosciences
Institution
University of Cambridge
Address
Box 165Addenbrookes Hospital
City or Town
Cambridge
State or Province
N/A
Zip or Postal Code
CB2 2QQ
Country
United Kingdom
Email Address
belinda.lennox@psych.ox.ac.uk